Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 8
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
8| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10364238 | EKTERLYsebetralstat | substance, product | Nov 2035 |
| 10611758 | EKTERLYsebetralstat | use | Nov 2035 |
| 11001578 | EKTERLYsebetralstat | substance, product | Nov 2035 |
| 11084809 | EKTERLYsebetralstat | substance, product | Nov 2035 |
| 11198691 | EKTERLYsebetralstat | use | Nov 2035 |
| 11739068 | EKTERLYsebetralstat | use | Jun 2037 |
| 11230537 | EKTERLYsebetralstat | substance, product | Dec 2037 |
| 11234939 | EKTERLYsebetralstat | product | Jan 2039 |
| Product | Exclusivity | Until |
|---|---|---|
| EKTERLYSEBETRALSTAT | ODE-534 Orphan drug | Jul 2032 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| EKTERLY | sebetralstat | tablet, oral | 82928-300NDA |
Enquiry
Common questions
- Is KalVista Pharmaceuticals Ltd FDA approved?
- KalVista Pharmaceuticals Ltd holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does KalVista Pharmaceuticals Ltd make?
- 1 product is listed under KalVista Pharmaceuticals Ltd in the openFDA NDC Directory, most often as tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.